Latest SpectraCure News & Updates

See the latest news and media coverage for SpectraCure. We track all announcements, press releases, and industry mentions in real time, all in one place.

Company icon
SpectraCure

Developer of photodynamic therapy systems for solid tumors

spectracure.com
Headquarters
Sweden
Founded year
2003
Company type
Public company
Number of employees
20–50

Last updated

Latest news about SpectraCure

In short: SpectraCure initiated a 34 MSEK rights issue to fund clinical trials and phase 3 preparations after reporting narrow losses in early 2026.

Company announcements

SpectraCure

SpectraCure held its annual general meeting on May 27, 2026

The annual general meeting adopted the income statement, granted discharge from liability, re-elected the board, decided on no dividend, authorization for share issue, and guidelines for remuneration.

Unlock all announcements with a

Media coverage

Affärsvärlden

New flag in SpectraCure's rights issue

The medical technology company SpectraCure has released the memorandum for its rights issue of SEK 34 million and Emissionsguiden raises a new flag for insufficient information.

Affärsvärlden

Four flags in SpectraCure's rights issue

The medical technology company SpectraCure is carrying out a rights issue that could bring the company 34 million SEK before costs. The Emission Guide raises four flags.

Dagens industri

Spectracure reduces the loss slightly

The medical technology company Spectracure, listed on the Nasdaq First North trading platform, reports a net result of -6.1 million kronor for the...

Nyheter24

Spectracure applies for permission for clinical study of primary prostate cancer

The research company Spectracure has decided to apply for permission to initiate a clinical study for primary localized prostate cancer. This appears from a press release.The board and management have during...

Unlock all articles with a

Never miss news about SpectraCure

Track SpectraCure and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.